U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06847542) titled 'A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD' on Feb. 21.
Brief Summary: The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
Study Start Date: June 19, 2025
Study Type: INTERVENTIONAL
Condition:
Neovascular Age-related Macular Degeneration
Intervention:
DEVICE: Susvimo PDS Implant
Ranizumab will be administered via a PDS implant per the schedule described in the arm.
DRUG: Ranibizumab
Participants will receive ranibizu...